Novartis improves ranking in 2016 Access to Medicine Index
(Thomson Reuters ONE) -
Novartis International AG /
Novartis improves ranking in 2016 Access to Medicine Index
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Novartis ranks third in 2016 ranking
* Company tops the industry in access-to-medicine management and capacity
building
* Novartis integrated access strategy addressing all income segments stands
out as best practice
The digital press release with multimedia content can be accessed here:
Basel, November 14, 2016 - Novartis ranked third in the 2016 Access to Medicine
Index (up from 4th place in 2014), in recognition of its efforts to improve
worldwide access to healthcare.
The Index measures the performance of the top-20 pharmaceutical companies to
improve access to medicines and healthcare in developing countries, and is
conducted every other year. It covers seven categories, including access-to-
medicine management, capacity building, pricing, manufacturing and distribution.
"We share the fundamental aim of the Access to Medicine Index: to close the
access gap in developing countries," said Joseph Jimenez, CEO of Novartis. "We
are delighted that our actions have been recognized, but more work is needed. In
order to improve access even further, we will continue to work on creating more
scalable and sustainable approaches to increase the affordability and
availability of medicines to underserved patients."
Novartis was the industry leader in access-to-medicine management and capacity
building. The company also performed strongly on R&D, with a pipeline spanning
all four disease categories in the scope of the Index. Novartis also rose to the
top three in pricing, manufacturing and distribution, significantly expanding
its equitable pricing strategies.
Two programs in particular were recognized as best practice: Novartis Access,
the portfolio of 15 on- and off-patent medicines to fight chronic diseases in
lower-income countries; and ComHIP, a program supported by the Novartis
Foundation and its partners to evaluate the impact of an innovative healthcare
model on hypertension control and self-management in Ghana, Africa. Furthermore,
the company's long-term product donations for liver fluke and leprosy stood out
for their reach and broad coverage, according to the Index.
In capacity building, Novartis improved on its already strong performance in
2014. The Index highlights the company's engagement with the University of Cape
Town in South Africa on malaria and tuberculosis drug discovery, as well as the
award-winning SMS for Life program, a public-private partnership to manage
medicine stocks in sub-Saharan Africa. SMS for Life has been piloted in more
than 10,000 healthcare facilities and is being scaled up using smartphones and
tablet computers.
Novartis pursues a combination of approaches to expand access to its medicines -
philanthropy, zero-profit initiatives and social ventures. In 2015, the
company's access-to-healthcare initiatives reached almost 66 million patients
globally, and training and healthcare service programs reached 12 million
people.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in
approximately 180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Carrie Scott
Novartis Global Media Relations Novartis Corporate Brand & Reputation
+41 61 324 7999 (direct) +41 61 324 3435 (direct)
+41 79 593 4202 (mobile) +41 79 264 4121 (mobile)
eric.althoff(at)novartis.com carrie.scott(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media Release (PDF):
http://hugin.info/134323/R/2056472/770254.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2016 - 01:01 Uhr
Sprache: Deutsch
News-ID 506578
Anzahl Zeichen: 6245
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis improves ranking in 2016 Access to Medicine Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
